Latest News of GSK
GSK's RSV vaccine approved in Canada for adults aged 50 to 59
By Yahoo! Finance |
2 days ago
GlaxoSmithKline's AREXVY vaccine has been approved in Canada for adults aged 50-59 to prevent RSV lower respiratory tract disease. The expanded approval follows positive Phase III trial results, with ...
GSK PLC (GSK) Q3 2024 Earnings Call Highlights: Strong Specialty Medicines Growth Amid Vaccine ...
By Yahoo! Finance |
1 week ago
GSK anticipates profitable growth in 2025, led by Specialty Medicines. Sales of Shingrix in China face challenges, with flexibility in the Zhifei contract. Arexvy sales show promise internationally, w...
GSK Takes A Header As Vaccine Sales Plummet, Miss
By Investor's Business Daily |
1 week ago
GSK stock plummeted due to declining vaccine sales in Q3. Sales dropped 2% to 8.01 billion pounds, missing analyst estimates. Vaccine sales, notably for Arexvy and Shingrix, fell, but GSK maintains it...
-
GSK to acquire CMG1A46 from Chimagen Biosciences
By Yahoo! Finance | 1 week agoGSK has acquired CMG1A46, a dual CD19 and CD20-targeted T cell-engager from Chimagen for $300M upfront....
-
FTSE 100 Live 30 October: Index seen lower, GSK and Next post updates
By Yahoo! Finance | 1 week agoGSK reported a 15% decline in vaccine sales, offset by a 19% rise in Speciality Medicines revenue in Q3. Operating profit dropped 86% due to a £1.8 billion charge....
-
GSK Net Profit Expected to Rise, Turnover to Fall -- Earnings Preview
By MarketWatch | 1 week agoGSK is set to announce Q3 results, with forecasts of 8.00 billion pounds in turnover and a net profit decrease to 1.78 billion pounds. Concerns remain about vaccine sales, particularly for Arexvy and ...
-
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
By Yahoo! Finance | 2 weeks agoGSK plc presented promising preliminary data on Arexvy vaccine for adults aged 18-49 at risk for lower respiratory tract disease. The vaccine aims to protect a wider range of adults from the serious e...
-
Cambridge University and GSK sign immunology R&D collaboration
By Yahoo! Finance | 2 weeks agoGSK invests £50m in a partnership with Cambridge University to accelerate immune-related disease research. The collaboration aims to improve current treatments and develop new ones for respiratory an...
-
mRNA licensing agreements surge 800% amid GSK lawsuits
By Yahoo! Finance | 2 weeks agoThe success of mRNA technology in Covid-19 vaccines has led to an 800% increase in licensing deal values for mRNA-based pharmaceuticals. Major companies are heavily investing in mRNA technology, but r...
-
GSK's depemokimab shows promise in Phase III trials for chronic rhinosinusitis
By Yahoo! Finance | 3 weeks agoGSK's Phase III trials of depemokimab in CRSwNP patients showed significant improvements compared to placebo, meeting primary endpoints. The drug's potential as a convenient treatment option is promis...
-
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
By Yahoo! Finance | 3 weeks agoGSK plc announced positive results from phase 3 trials for depemokimab in treating chronic rhinosinusitis with nasal polyps. The trials met primary endpoints, showing efficacy and safety in reducing p...
-
Jim Cramer Says GSK plc (GSK) 'Goes Higher'
By Yahoo! Finance | 3 weeks agoThe article discusses Jim Cramer's insights on stocks such as GSK plc and market dynamics during earnings season. It also covers GSK's settlement over Zantac and its ranking in Cramer's list. The impo...
-
GSK shares jump after landmark £1.68bn heartburn drug settlement
By Yahoo! Finance | 4 weeks agoGSK's shares rose following a $2.2 billion settlement for Zantac lawsuits in the US. The settlement with 80,000 claimants alleging cancer risks was seen as a win for GSK, which will not impact its gro...
-
GSK Shares Climb on $2.2 Bln Zantac Lawsuit Settlement
By MarketWatch | 4 weeks agoBritish pharmaceutical company GSK's shares rose as it settled the majority of U.S. lawsuits over its heartburn drug Zantac. GSK agreed to pay $2.2 billion to resolve 93% of cases, boosting shares by ...
-
GSK shares jump after settlement of 80,000 Zantac lawsuits in U.S
By Yahoo! Finance | 4 weeks agoGSK's stock rose 6% as they agreed to a $2.2 billion settlement for Zantac cancer lawsuits in the U.S., lower than expected. The settlement resolves 93% of cases, easing concerns for investors....